Table 1.
Demographic and clinical characteristics and programmed death‐ligand 1 expression in 344 patients with esophageal cancer
| Characteristic | No. of patients n = 344 | PD‐L1−TCs n = 294 | PD‐L1 + TCs n = 50 | P a | PD‐L1−ICs n = 259 | PD‐L1 + ICs n = 85 | P a |
|---|---|---|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | |||
| Sex | |||||||
| Male | 268 (77.9) | 233 (79.3) | 35 (70.0) | 0.104 | 202 (78.0) | 66 (77.6) | 0.947 |
| Female | 76 (22.1) | 61 (20.7) | 15 (30.0) | 57 (22.0) | 19 (22.4) | ||
| Age (years) | |||||||
| <60 | 226 (65.7) | 195 (66.3) | 31 (62.0) | 0.329 | 169 (65.3) | 57 (67.1) | 0.761 |
| ≥60 | 118 (34.3) | 99 (33.7) | 19 (38.0) | 90 (34.7) | 28 (32.9) | ||
| Tumor location | |||||||
| Upper esophagus | 44 (12.8) | 36 (12.2) | 8 (16.0) | 0.224 | 33 (12.7) | 11 (12.9) | 0.328 |
| Middle esophagus | 228 (66.3) | 192 (65.3) | 36 (72.0) | 167 (64.5) | 61 (71.8) | ||
| Lower esophagus | 72 (20.9) | 66 (22.4) | 6 (12.0) | 59 (22.8) | 13 (15.3) | ||
| Tumor differentiation | |||||||
| High | 109 (31.7) | 96 (32.7) | 13 (26.0) | 0.643 | 84 (32.4) | 25 (29.4) | 0.710 |
| Moderate | 198 (57.6) | 167 (56.8) | 31 (62.0) | 149 (57.5) | 49 (57.6) | ||
| Low | 37 (10.7) | 31 (10.5) | 6 (12.0) | 26 (10.0) | 11 (12.9) | ||
| T stageb | |||||||
| T1 | 1 (0.3) | 1 (0.3) | 0 (0) | 0.045 | 0 (0) | 1(1.2) | 0.100 |
| T2 | 38 (11.0) | 27 (9.2) | 11 (22.0) | 25 (9.7) | 13(15.3) | ||
| T3 | 241 (70.1) | 208 (70.7) | 33 (66.0) | 188 (72.6) | 53 (62.4) | ||
| T4 | 64 (18.6) | 58 (19.7) | 6 (12.0) | 46 (17.8) | 18 (21.2) | ||
| N stageb | |||||||
| N0 | 167 (48.5) | 143 (48.6) | 24 (48.0) | 0.933 | 120 (46.3) | 47 (55.3) | 0.151 |
| N1 | 177 (51.5) | 151 (51.4) | 26 (52.0) | 139 (53.7) | 38 (44.7) | ||
| Pathologic stageb | |||||||
| Stage IIA | 144 (41.9) | 122 (41.5) | 22 (44.0) | 0.007 | 106 (40.9) | 38 (44.7) | 0.020 |
| Stage IIB | 18 (5.2) | 11 (3.7) | 7 (14.0) | 9 (3.5) | 9 (10.6) | ||
| Stage III | 182 (52.9) | 161 (54.8) | 21 (42.0) | 144 (55.6) | 38 (44.7) | ||
| Treatment | |||||||
| Surgery alone | 197 (57.3) | 166 (56.5) | 31 (62.0) | 0.464 | 153 (59.1) | 44 (51.8) | 0.237 |
| Surgery + Radiotherapy | 147 (42.7) | 128 (43.5) | 19 (38.0) | 106 (40.9) | 41 (48.2) | ||
| EGFR status | |||||||
| Low | 86 (25.0) | 67 (22.8) | 19 (38.0) | 0.022 | 56 (21.6) | 30 (35.3) | 0.012 |
| High | 258 (75.0) | 227 (77.2) | 31 (62.0) | 203 (78.4) | 55 (64.7) | ||
EGFR, epidermal growth factor receptor; IC, immune cell; PD‐L1, programmed death‐ligand 1; TC, tumor cell.
a
P ≤ 0.05 was considered statistically significant.
b
Union for International Cancer Control, TNM Classification of Malignant Tumors.